MedTrace Logo

P2X7 Receptor, Inflammation and Neurodegenerative Diseases

NCT03918616 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2019-08-13

No results posted yet for this study

Summary

Parkinson disease (PD) is a chronic degenerative disease characterized by a progressive loss of dopaminergic neurons in the substantia nigra. Its pathophysiological mechanisms are still partially unknown; a main role seems to be played by chronic neuroinflammation. A few reports have addressed the possible involvement of the inflammasome in PD, just describing the protective effect of P2X7 purinergic receptor (P2X7R) blockers in murine models of the disease and in microglial cells, where NLRP3 is activated by α-Synuclein, triggering a neuroinflammation that contributes to degeneration of dopaminergic neurons. It is still unclear whether, in addition to the increased brain expression and function of the nucleotide-binding domain, leucine-rich repeat, pyrin domain containing type 3 (NLRP3) inflammasome platform, a systemic activation of such complex might participate in the pathogenesis of PD, which could be the role of the P2X7R in this scenario, and whether such patterns undergo any specific epigenetic regulation. The present study has been designed to address these issues.

Conditions

Interventions

DRUG

Memantine, Dopamine receptor-agonists

The study do not provide any experimental drugs. Patientes will receive treatment routinary used by Neurologist for these diseases.

Sponsors & Collaborators

  • University of Pisa

    lead OTHER

Principal Investigators

  • Anna Solini, MD, PhD · Univeristy of Pisa

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-20
Primary Completion
2018-12-30
Completion
2019-03-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03918616 on ClinicalTrials.gov